{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-037767","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.150187+00:00","generated_at":"2026-06-12T07:10:53.912468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insmed Q2 ARIKAYCE rev $77.2M (+18%), raises FY guide $295-305M; net loss $244.8M","bullets":["ARIKAYCE global revenue $77.2M, 18% YoY growth, highest quarterly sales since launch.","Full-year 2023 ARIKAYCE revenue guidance raised to $295-305M from $285-300M.","Net loss $244.8M ($1.78/sh) vs $95.6M loss in Q2 2022; R&D costs rose due to $76.5M acquisition of Adrestia.","Cash, equivalents, marketable securities $918M as of June 30, down from $999M at March 31.","Upcoming catalysts: ARISE topline data Sept 2023; ASPEN Phase 3 data expected Q2 2024; TPIP interim data H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-037767","json":"https://secwatch.observer/filing/0001140361-23-037767.json","markdown":"https://secwatch.observer/filing/0001140361-23-037767.md","text":"https://secwatch.observer/filing/0001140361-23-037767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123037767/0001140361-23-037767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123037767/brhc20056931_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:10:53.912468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}